Intercept Pharmaceuticals Company Profile (NASDAQ:ICPT)

About Intercept Pharmaceuticals

Intercept Pharmaceuticals logoIntercept Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company's product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions. The Company's product candidate, obeticholic acid (OCA), is a bile acid analog, a chemical substance that has a structure based on a naturally occurring human bile acid that selectively binds to and activates the farnesoid X receptor (FXR). The Company is developing OCA for the treatment of liver diseases, such as primary biliary cirrhosis (PBC), non-alcoholic steatoheptitis (NASH), primary sclerosing cholangitis (PCS) and biliary atresia. The Company is also developing other products INT-767 for the treatment of fibrosis and INT-777 for the treatment of type 2 diabetes.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: ICPT
  • CUSIP: 45845P10
Key Metrics:
  • Previous Close: $115.93
  • 50 Day Moving Average: $113.45
  • 200 Day Moving Average: $128.79
  • 52-Week Range: $96.63 - $177.93
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -7.83
  • P/E Growth: -1.13
  • Market Cap: $2.88B
  • Outstanding Shares: 24,808,000
  • Beta: -2.14
  • Net Margins: -3,287.95%
  • Return on Equity: -66.97%
  • Return on Assets: -48.90%
  • Debt-to-Equity Ratio: 0.81%
  • Current Ratio: 14.57%
  • Quick Ratio: 14.57%
Additional Links:
Companies Related to Intercept Pharmaceuticals:

Analyst Ratings

Consensus Ratings for Intercept Pharmaceuticals (NASDAQ:ICPT) (?)
Ratings Breakdown: 4 Sell Ratings, 3 Hold Ratings, 10 Buy Ratings
Consensus Rating:Hold (Score: 2.35)
Consensus Price Target: $187.12 (61.41% upside)

Analysts' Ratings History for Intercept Pharmaceuticals (NASDAQ:ICPT)
DateFirmActionRatingPrice TargetDetails
2/24/2017WedbushReiterated RatingOutperform$224.00View Rating Details
2/23/2017Needham & Company LLCReiterated RatingHoldView Rating Details
2/23/2017Cantor FitzgeraldSet Price TargetSell$60.00View Rating Details
2/16/2017Robert W. BairdReiterated RatingOutperform$332.00View Rating Details
2/16/2017BMO Capital MarketsReiterated RatingOutperform$198.00View Rating Details
2/16/2017FBR & CoReiterated RatingMarket Perform$200.00View Rating Details
2/11/2017Oppenheimer Holdings, Inc.Set Price TargetBuy$200.00View Rating Details
2/10/2017Cowen and CompanyReiterated RatingOutperform$225.00View Rating Details
11/6/2016JMP SecuritiesReiterated RatingBuyView Rating Details
10/14/2016Leerink SwannReiterated RatingPositive$159.00View Rating Details
9/28/2016Wells Fargo & CompanyReiterated RatingBuyView Rating Details
9/22/2016Credit Suisse GroupReiterated RatingBuyView Rating Details
8/5/2016Morgan StanleyReiterated RatingSell$80.00View Rating Details
8/5/2016LaidlawDowngradeBuy -> Sell$345.00 -> $105.00View Rating Details
6/1/2016Barclays PLCReiterated RatingBuy$200.00 -> $205.00View Rating Details
5/31/2016Goldman Sachs Group, Inc. (The)Boost Price TargetNeutral$114.00 -> $128.00View Rating Details
4/9/2016Bank of America CorpReiterated RatingSell$144.00View Rating Details
1/28/2016S&P Equity ResearchReiterated RatingAverage$100.60 -> $111.91View Rating Details
8/7/2015Janney Montgomery ScottReiterated RatingBuyView Rating Details
7/24/2015Royal Bank of CanadaReiterated RatingOutperform$490.00View Rating Details
7/1/2015MLV & Co.Reiterated RatingHoldView Rating Details
3/27/2015Deutsche Bank AGBoost Price TargetBuy$300.00 -> $400.00View Rating Details
3/20/2015NomuraSet Price TargetBuy$440.00View Rating Details
(Data available from 2/24/2015 forward)


Earnings History for Intercept Pharmaceuticals (NASDAQ:ICPT)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/23/2017Q416($3.74)($4.84)$8.96 million$13.00 millionViewN/AView Earnings Details
11/3/2016Q316($3.82)($3.59)$4.77 million$4.70 millionViewN/AView Earnings Details
8/4/2016Q216($3.69)($3.14)$1.72 million$5.52 millionViewN/AView Earnings Details
5/5/2016Q1($3.60)($5.17)$0.64 millionViewN/AView Earnings Details
2/23/2016Q415($3.15)($3.62)$0.43 million$0.45 millionViewListenView Earnings Details
11/9/2015Q315($2.74)($2.10)$0.42 million$0.45 millionViewN/AView Earnings Details
8/5/2015Q215($1.95)($1.99)$2.17 million$0.45 millionViewN/AView Earnings Details
5/11/2015Q115($1.75)($1.78)$1.70 million$1.70 millionViewListenView Earnings Details
3/2/2015Q414($1.53)($1.63)$0.42 million$0.04 millionViewN/AView Earnings Details
11/6/2014Q3($1.02)($1.69)$0.46 million$0.45 millionViewN/AView Earnings Details
8/11/2014Q214($0.12)($0.79)$400.00 million$405.40 millionViewN/AView Earnings Details
5/7/2014($0.72)($1.59)ViewN/AView Earnings Details
3/14/2014Q4 13($0.70)($0.64)ViewN/AView Earnings Details
11/14/2013Q313($0.51)($1.65)$0.89 millionViewN/AView Earnings Details
8/13/2013Q2 2013($0.51)($0.79)$0.40 million$0.41 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Intercept Pharmaceuticals (NASDAQ:ICPT)
Current Year EPS Consensus Estimate: $-15.82 EPS
Next Year EPS Consensus Estimate: $-14.81 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20164($4.29)($3.65)($3.83)
Q2 20165($4.12)($3.00)($3.65)
Q3 20164($4.41)($2.80)($3.75)
Q4 20164($4.61)($2.65)($3.84)
Q1 20173($4.19)($2.67)($3.42)
Q2 20173($4.04)($2.76)($3.56)
Q3 20173($3.82)($2.82)($3.48)
Q4 20172($3.52)($2.89)($3.21)
(Data provided by Zacks Investment Research)


Dividend History for Intercept Pharmaceuticals (NASDAQ:ICPT)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for Intercept Pharmaceuticals (NASDAQ:ICPT)
Insider Ownership Percentage: 9.20%
Institutional Ownership Percentage: 82.28%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
1/31/2017Lisa BrightInsiderSell134$108.96$14,600.64View SEC Filing  
1/9/2017David ShapiroCMOSell1,565$106.01$165,905.65View SEC Filing  
1/3/2017David ShapiroCMOSell988$103.92$102,672.96View SEC Filing  
1/3/2017Mark PruzanskiCEOSell2,802$103.92$291,183.84View SEC Filing  
1/3/2017Rachel McminnInsiderSell816$103.92$84,798.72View SEC Filing  
12/2/2016David ShapiroCMOSell1,350$99.75$134,662.50View SEC Filing  
11/25/2016Lisa BrightInsiderSell249$113.60$28,286.40View SEC Filing  
10/31/2016Rachel McminnInsiderSell129$123.82$15,972.78View SEC Filing  
10/10/2016David ShapiroCMOSell411$153.34$63,022.74View SEC Filing  
10/3/2016Barbara Gayle DuncanCAOSell147$163.20$23,990.40View SEC Filing  
10/3/2016David ShapiroCMOSell1,513$163.08$246,740.04View SEC Filing  
10/3/2016Lisa BrightInsiderSell155$163.20$25,296.00View SEC Filing  
10/3/2016Mark PruzanskiCEOSell705$163.20$115,056.00View SEC Filing  
9/26/2016David ShapiroCMOSell3,545$165.08$585,208.60View SEC Filing  
9/20/2016Mark PruzanskiCEOSell35,000$165.00$5,775,000.00View SEC Filing  
8/25/2016Lisa BrightInsiderSell246$159.00$39,114.00View SEC Filing  
8/1/2016Rachel McminnInsiderSell125$176.57$22,071.25View SEC Filing  
7/5/2016Barbara Gayle DuncanCAOSell146$145.11$21,186.06View SEC Filing  
7/5/2016David ShapiroCMOSell163$145.11$23,652.93View SEC Filing  
7/5/2016Lisa BrightInsiderSell155$145.11$22,492.05View SEC Filing  
7/5/2016Mark PruzanskiCEOSell714$145.11$103,608.54View SEC Filing  
5/25/2016Lisa BrightInsiderSell251$137.50$34,512.50View SEC Filing  
5/2/2016Rachel McminnInsiderSell130$147.49$19,173.70View SEC Filing  
4/4/2016Barbara Gayle DuncanCFOSell144$130.76$18,829.44View SEC Filing  
4/4/2016David ShapiroCMOSell165$130.76$21,575.40View SEC Filing  
4/4/2016Lisa BrightInsiderSell153$130.76$20,006.28View SEC Filing  
4/4/2016Mark PruzanskiCEOSell708$130.76$92,578.08View SEC Filing  
2/25/2016Lisa BrightInsiderSell241$115.22$27,768.02View SEC Filing  
2/1/2016Rachel McminnInsiderSell128$103.56$13,255.68View SEC Filing  
1/13/2016Lisa BrightinsiderSell728$125.52$91,378.56View SEC Filing  
1/4/2016Barbara Gayle DuncanCFOSell468$145.90$68,281.20View SEC Filing  
1/4/2016David ShapiroCMOSell533$145.90$77,764.70View SEC Filing  
1/4/2016Mark PruzanskiCEOSell2,126$145.90$310,183.40View SEC Filing  
1/4/2016Rachel McminnInsiderSell469$145.90$68,427.10View SEC Filing  
11/25/2015Lisa BrightInsiderSell1,150$182.96$210,404.00View SEC Filing  
11/16/2015David ShapiroCMOSell4,264$178.53$761,251.92View SEC Filing  
11/10/2015David ShapiroCMOSell3,500$204.15$714,525.00View SEC Filing  
11/10/2015Klaus R. Dr VeitingerDirectorSell1,000$198.25$198,250.00View SEC Filing  
11/2/2015Rachel McminnInsiderSell125$160.24$20,030.00View SEC Filing  
10/2/2015Barbara Gayle DuncanCFOSell1,054$163.17$171,981.18View SEC Filing  
10/2/2015David ShapiroCMOSell1,140$160.12$182,536.80View SEC Filing  
9/21/2015Nicole WilliamsDirectorSell973$194.82$189,559.86View SEC Filing  
9/15/2015David ShapiroCMOSell3,500$191.28$669,480.00View SEC Filing  
8/17/2015David ShapiroCMOSell4,272$209.37$894,428.64View SEC Filing  
7/20/2015Nicole WilliamsDirectorSell973$279.01$271,476.73View SEC Filing  
7/10/2015Mark PruzanskiCEOSell12,500$250.00$3,125,000.00View SEC Filing  
7/6/2015Luciano AdoriniInsiderSell4,067$579.93$2,358,575.31View SEC Filing  
7/1/2015Barbara Gayle DuncanCFOSell1,000$242.10$242,100.00View SEC Filing  
7/1/2015David ShapiroCMOSell3,781$238.66$902,373.46View SEC Filing  
6/22/2015Nicole WilliamsDirectorSell974$265.14$258,246.36View SEC Filing  
6/15/2015David ShapiroCMOSell3,500$241.58$845,530.00View SEC Filing  
6/8/2015Luciano AdoriniInsiderSell4,000$248.40$993,600.00View SEC Filing  
5/11/2015Klaus R Dr VeitingerDirectorSell391$279.07$109,116.37View SEC Filing  
5/6/2015Luciano AdoriniInsiderSell4,000$259.97$1,039,880.00View SEC Filing  
4/20/2015Nicole WilliamsDirectorSell974$278.50$271,259.00View SEC Filing  
4/6/2015Luciano AdoriniInsiderSell4,000$269.64$1,078,560.00View SEC Filing  
4/2/2015David ShapiroCMOSell3,459$275.25$952,089.75View SEC Filing  
3/26/2015Orbimed Advisors LlcDirectorSell157,200$286.75$45,077,100.00View SEC Filing  
3/25/2015Orbimed Advisors LlcDirectorSell207,800$274.41$57,022,398.00View SEC Filing  
3/24/2015Jonathan SilversteinDirectorSell45,600$272.00$12,403,200.00View SEC Filing  
3/23/2015Jonathan SilversteinDirectorSell159,400$275.18$43,863,692.00View SEC Filing  
3/16/2015David ShapiroCMOSell3,500$286.90$1,004,150.00View SEC Filing  
1/12/2015Klaus R Dr VeitingerDirectorSell233$150.01$34,952.33View SEC Filing  
1/5/2015Barbara Gayle DuncanCFOSell141$176.49$24,885.09View SEC Filing  
1/5/2015Daniel Paul ReganInsiderSell146$176.49$25,767.54View SEC Filing  
1/5/2015David ShapiroCMOSell664$172.63$114,626.32View SEC Filing  
1/5/2015Mark PruzanskiCEOSell461$176.49$81,361.89View SEC Filing  
1/2/2015Barbara Gayle DuncanCFOSell1,000$156.40$156,400.00View SEC Filing  
11/17/2014David ShapiroCMOSell4,790$158.82$760,747.80View SEC Filing  
11/12/2014Srinivas AkkarajuDirectorBuy2,000$167.19$334,380.00View SEC Filing  
11/10/2014Klaus R Dr VeitingerDirectorSell233$175.95$40,996.35View SEC Filing  
11/3/2014Mark PruzanskiCEOSell10,000$259.41$2,594,100.00View SEC Filing  
10/10/2014Klaus R Dr VeitingerDirectorSell391$223.65$87,447.15View SEC Filing  
10/2/2014David ShapiroCMOSell5,020$231.63$1,162,782.60View SEC Filing  
10/1/2014Barbara Gayle DuncanCFOSell1,000$233.12$233,120.00View SEC Filing  
10/1/2014David ShapiroCMOSell4,188$231.17$968,139.96View SEC Filing  
10/1/2014Mark PruzanskiCEOSell10,000$228.82$2,288,200.00View SEC Filing  
9/15/2014David ShapiroCMOSell4,000$281.19$1,124,760.00View SEC Filing  
9/10/2014Klaus R Dr VeitingerDirectorSell391$280.50$109,675.50View SEC Filing  
9/2/2014Mark PruzanskiCEOSell10,000$286.49$2,864,900.00View SEC Filing  
8/27/2014David ShapiroCMOSell10,000$293.93$2,939,300.00View SEC Filing  
8/26/2014Orbimed Advisors LlcDirectorSell111,258$298.06$33,161,559.48View SEC Filing  
8/25/2014Jonathan SilversteinDirectorSell50,000$295.59$14,779,500.00View SEC Filing  
8/15/2014David ShapiroCMOSell4,774$291.49$1,391,573.26View SEC Filing  
8/12/2014Daniel Paul ReganInsiderSell8,124$325.70$2,645,986.80View SEC Filing  
8/12/2014Klaus R Dr VeitingerDirectorSell316$345.62$109,215.92View SEC Filing  
8/1/2014Mark PruzanskiCEOSell10,000$226.72$2,267,200.00View SEC Filing  
7/10/2014Klaus R Dr VeitingerDirectorSell391$219.15$85,687.65View SEC Filing  
7/7/2014Lorenzo TallarigoDirectorSell2,000$243.06$486,120.00View SEC Filing  
7/2/2014David ShapiroCMOSell5,036$244.73$1,232,460.28View SEC Filing  
7/1/2014Mark PruzanskiCEOSell10,000$250.61$2,506,100.00View SEC Filing  
6/16/2014David ShapiroCMOSell4,000$278.15$1,112,600.00View SEC Filing  
6/2/2014Mark PruzanskiCEOSell10,000$230.60$2,306,000.00View SEC Filing  
5/9/2014Lorenzo TallarigoDirectorSell2,007$254.68$511,142.76View SEC Filing  
5/1/2014Mark PruzanskiCEOSell10,000$263.17$2,631,700.00View SEC Filing  
4/16/2014Mark PruzanskiCEOSell10,000$242.22$2,422,200.00View SEC Filing  
4/14/2014Barbara Gayle DuncanCFOSell1,154$279.00$321,966.00View SEC Filing  
4/10/2014Lorenzo TallarigoDirectorSell349,318$317.71$110,981,821.78View SEC Filing  
4/9/2014Orbimed Advisors LlcDirectorSell81,305$320.00$26,017,600.00View SEC Filing  
4/7/2014Luciano AdoriniInsiderSell2,000$283.90$567,800.00View SEC Filing  
4/2/2014David ShapiroCMOSell5,393$331.83$1,789,559.19View SEC Filing  
3/17/2014David ShapiroCMOSell4,456$437.49$1,949,455.44View SEC Filing  
2/14/2014Paolo FundaroDirectorSell7,246$375.26$2,719,133.96View SEC Filing  
1/16/2014Mark PruzanskiCEOSell10,000$273.68$2,736,800.00View SEC Filing  
1/16/2014Srinivas AkkarajuDirectorSell3,250$267.94$870,805.00View SEC Filing  
1/8/2014David ShapiroCMOSell4,928$71.85$354,076.80View SEC Filing  
1/7/2014Lorenzo TallarigoDirectorSell1,839$67.41$123,966.99View SEC Filing  
1/7/2014Luciano AdoriniInsiderSell1,634$67.41$110,147.94View SEC Filing  
12/16/2013David ShapiroCMOSell5,016$62.11$311,543.76View SEC Filing  
10/21/2013Francesco MicheliMajor ShareholderSell124,912$62.50$7,807,000.00View SEC Filing  
10/21/2013Jonathan SilversteinDirectorSell40,088$62.50$2,505,500.00View SEC Filing  
10/21/2013Luciano AdoriniInsiderSell2,000$55.51$111,020.00View SEC Filing  
10/15/2013Francesco MicheliMajor ShareholderSell1,123,415$62.50$70,213,437.50View SEC Filing  
10/15/2013Orbimed Advisors LlcDirectorSell376,585$62.50$23,536,562.50View SEC Filing  
10/2/2013David ShapiroCMOSell4,392$72.80$319,737.60View SEC Filing  
9/20/2013Luciano AdoriniInsiderSell2,000$61.07$122,140.00View SEC Filing  
9/17/2013Mark PruzanskiCEOSell25,000$52.00$1,300,000.00View SEC Filing  
9/13/2013Mark PruzanskiCEOSell12,500$49.02$612,750.00View SEC Filing  
8/20/2013Luciano AdoriniInsiderSell2,000$44.18$88,360.00View SEC Filing  
8/16/2013David ShapiroCMOSell5,016$49.20$246,787.20View SEC Filing  
8/15/2013David ShapiroCMOSell4,754$45.04$214,120.16View SEC Filing  
8/12/2013Mark PruzanskiCEOSell12,500$45.98$574,750.00View SEC Filing  
8/12/2013Paolo FundaroDirectorSell4,759$46.13$219,532.67View SEC Filing  
7/22/2013Luciano AdoriniInsiderSell2,000$49.44$98,880.00View SEC Filing  
7/15/2013Mark PruzanskiCEOSell25,000$50.05$1,251,250.00View SEC Filing  
7/9/2013Mark PruzanskiCEOSell37,500$46.36$1,738,500.00View SEC Filing  
7/8/2013Barbara Gayle DuncanCFOSell25,000$45.39$1,134,750.00View SEC Filing  
7/2/2013David ShapiroCMOSell4,369$43.63$190,619.47View SEC Filing  
6/26/2013Mark PruzanskiCEOSell12,500$40.06$500,750.00View SEC Filing  
6/20/2013Luciano AdoriniInsiderSell2,000$37.07$74,140.00View SEC Filing  
6/20/2013Mark PruzanskiCEOSell25,000$38.25$956,250.00View SEC Filing  
6/19/2013Barbara Gayle DuncanCFOSell50,575$34.50$1,744,837.50View SEC Filing  
6/17/2013David ShapiroCMOSell5,016$32.72$164,123.52View SEC Filing  
5/28/2013Barbara Gayle DuncanCFOSell6,225$34.50$214,762.50View SEC Filing  
5/20/2013Barbara Gayle DuncanCFOSell28,200$34.50$972,900.00View SEC Filing  
5/16/2013David ShapiroCMOSell5,016$31.31$157,050.96View SEC Filing  
4/9/2013David ShapiroCMOSell3,750$34.41$129,037.50View SEC Filing  
10/16/2012Jonathan SilversteinDirectorBuy333,334$15.00$5,000,010.00View SEC Filing  
(Data available from 1/1/2013 forward)


Latest Headlines for Intercept Pharmaceuticals (NASDAQ:ICPT)
News IconSell-side Target Update on Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) - Aiken Advocate (NASDAQ:ICPT) - February 23 at 10:50 PM
News IconAnalysts Peeling Back The Layers on Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT): Consensus Take - Winfield Review (NASDAQ:ICPT) - February 23 at 10:50 PM
News IconStock Buzz on Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT): Can They Meet the Earnings Target of $-3.58 - Winfield Review (NASDAQ:ICPT) - February 23 at 5:50 PM
News IconIntercept Pharmaceuticals Inc (ICPT) Releases Earnings Results, Misses Expectations By $-1.16 EPS - Highland Mirror (NASDAQ:ICPT) - February 23 at 5:50 PM logoIntercept reports 4Q loss (NASDAQ:ICPT) - February 23 at 5:50 PM logoIntercept (ICPT) Reports a Wider Q4 Loss (NASDAQ:ICPT) - February 23 at 5:50 PM logoNasdaq Slips as Biotechnology Shares Decline (NASDAQ:ICPT) - February 23 at 5:50 PM
News IconAnalysts Are Circling Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT): Where Do Research Brokers See It Going? - Winfield Review (NASDAQ:ICPT) - February 22 at 11:00 PM
News IconSmart Money Buying the Price Weakness of Intercept ... - Money Flow Index & Trends (NASDAQ:ICPT) - February 22 at 12:44 PM
News IconCan We Learn Anything From The Technical Chart of Intercept Pharmaceuticals, Inc. (ICPT)? - NY Stock News (NASDAQ:ICPT) - February 18 at 10:53 AM logoIntercept to Report 2016 Full Year Financial Results on February 23 and Present at Upcoming Conferences (NASDAQ:ICPT) - February 17 at 5:36 PM logoInvestors Are Betting Big Against Intercept Pharmaceuticals. Are They Wrong? (NASDAQ:ICPT) - February 17 at 8:34 AM logoAnalyst Activity – Wedbush Reiterates Outperform on Intercept Pharmaceuticals (NASDAQ:ICPT) (NASDAQ:ICPT) - February 16 at 4:42 PM
News IconMarket Check: Focusing on These Shares: Intercept Pharmaceuticals Inc. (ICPT) - Rives Journal (NASDAQ:ICPT) - February 15 at 8:57 PM
News IconIntercept Pharmaceuticals, Inc. (ICPT) Stock Rating Reaffirmed by Cantor Fitzgerald (NASDAQ:ICPT) - February 15 at 5:16 AM
News IconLarge Outflow of Money Witnessed in Intercept Pharmaceuticals, Inc (NASDAQ:ICPT) - February 14 at 7:13 PM logoIntercept Spikes on NASH Study Redesign (ICPT) (NASDAQ:ICPT) - February 14 at 7:13 PM logoIntercept Spikes on Liver Drug Study Redesign (NASDAQ:ICPT) - February 14 at 7:13 PM logoAnalysts Split On How To Read Intercept Switching Clinical Trial Endpoints (NASDAQ:ICPT) - February 13 at 6:51 PM
News IconIntercept Pharmaceuticals, Inc. (NASDAQ:ICPT) Projected EPS At ... - Stock Observer (NASDAQ:ICPT) - February 12 at 10:43 PM logoHere's Why Shares Of Intercept Jumped Nearly 10% On Friday (NASDAQ:ICPT) - February 11 at 10:55 PM logoWhy Intercept Pharmaceuticals' Latest News Caused the Stock to Jump (NASDAQ:ICPT) - February 11 at 12:29 PM logoNoteworthy Friday Option Activity: WEB, ICPT, FCX (NASDAQ:ICPT) - February 10 at 11:34 PM logo7:07 am Intercept Pharma says will provide an update on the Phase 3 REGENERATE trial of obeticholic acid in NASH patients with liver fibrosis during a conference call today, Friday February 10 at 8:30 a.m. ET. (NASDAQ:ICPT) - February 10 at 11:34 PM logoIntercept Pharma: We Can't Enroll Our NASH Study so We're Changing the Study. Trust Us, All Good (NASDAQ:ICPT) - February 10 at 11:34 PM logoWhy Shares Of Intercept Pharma Are Soaring Today (NASDAQ:ICPT) - February 10 at 11:34 PM logoThis Analyst Bullish On Intercept Pharmaceuticals Inc (ICPT) Long-Term - Smarter Analyst (NASDAQ:ICPT) - February 10 at 6:33 PM logoIntercept to Provide Update on Phase 3 REGENERATE Trial of Obeticholic Acid for the Treatment of NASH Patients with Liver Fibrosis (NASDAQ:ICPT) - February 10 at 7:27 AM
News IconIntercept Pharmaceuticals, Inc. (NASDAQ:ICPT) Stock ABR At 2.16 - Stock Observer (NASDAQ:ICPT) - February 8 at 12:07 AM
News IconBrokerage Firm Analyst Consensus on Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT), HP Inc (NYSE:HPQ) - Providence Standard (NASDAQ:ICPT) - February 6 at 10:39 AM logoResearch Reports Coverage on Biotech Stocks -- Intercept Pharma, Aeterna Zentaris, Spark Therapeutics, and Aratana Therapeutics (NASDAQ:ICPT) - February 1 at 6:34 PM
News IconEarnings Snapshot & Analysts Target Update on Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT)? - Wall Street Beacon (NASDAQ:ICPT) - January 31 at 11:37 PM
News IconPeeling Back The Layers on Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT): Analysts & Street Weigh In - Wall Street Beacon (NASDAQ:ICPT) - January 31 at 4:35 AM
News IconIntercept Pharmaceuticals Inc ICPT Pharmaceuticals Healthcare Deals and Alliances Profile Prices from USD $250 (NASDAQ:ICPT) - January 28 at 5:52 AM
News IconSell-side Target Update on Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) Stock - Aiken Advocate (NASDAQ:ICPT) - January 27 at 7:47 PM
News IconIs There Inherent Value in Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT)? Analysts Delve Into The Stock - Wall Street Beacon (NASDAQ:ICPT) - January 27 at 7:47 PM
News IconEarnings in Full Force, Analysts Take Aim at Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) - Wall Street Beacon (NASDAQ:ICPT) - January 26 at 7:29 PM
News IconStock Target in Focus for Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) - Aiken Advocate (NASDAQ:ICPT) - January 26 at 5:16 AM
News IconSell-Side Ratings Review on Shares of Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) - Wall Street Beacon (NASDAQ:ICPT) - January 25 at 7:12 PM logoIntercept Pharmaceuticals Inc (ICPT) Stock Could Be Biotech's Grand Slam - (NASDAQ:ICPT) - January 25 at 7:12 PM logoIntercept Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : ICPT-US : January 24, 2017 (NASDAQ:ICPT) - January 24 at 6:34 PM
News IconIntercept Pharmaceuticals Inc (ICPT) Stock Could Be Biotech’s Grand Slam (NASDAQ:ICPT) - January 24 at 6:36 AM logoIntercept Pharmaceuticals Inc (ICPT) Stock Could Be Biotech’s Grand Slam (NASDAQ:ICPT) - January 24 at 6:16 AM
News IconAnalysts Pounding The Pavement on Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT): Consensus Update - Wall Street Beacon (NASDAQ:ICPT) - January 24 at 4:11 AM
News IconIntercept Pharmaceuticals, Inc. (NASDAQ:ICPT) Projected to Achieve EPS Of $-3.58 - Stock Observer (NASDAQ:ICPT) - January 22 at 5:41 PM logo3 Biotechs Likely to Be Acquired in 2017 (NASDAQ:ICPT) - January 22 at 2:01 PM
News IconIntercept Pharmaceuticals Inc (ICPT) is Downgraded by Needham to ... - Highland Mirror (NASDAQ:ICPT) - January 21 at 5:39 PM
News IconAnalysts Pull Back the Curtain on Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT): Consensus Update - Wall Street Beacon (NASDAQ:ICPT) - January 20 at 8:20 PM
News IconDevling Into Shares of Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT), What Are Analysts Predicting for 2017? - Wall Street Beacon (NASDAQ:ICPT) - January 20 at 3:16 PM logoIntercept Pharma downgraded by Needham (NASDAQ:ICPT) - January 20 at 3:16 PM


What is Intercept Pharmaceuticals' stock symbol?

Intercept Pharmaceuticals trades on the NASDAQ under the ticker symbol "ICPT."

Where is Intercept Pharmaceuticals' stock going? Where will Intercept Pharmaceuticals' stock price be in 2017?

17 brokerages have issued 12-month price targets for Intercept Pharmaceuticals' stock. Their forecasts range from $60.00 to $350.00. On average, they expect Intercept Pharmaceuticals' stock price to reach $187.12 in the next year.

When will Intercept Pharmaceuticals announce their earnings?

Intercept Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, February, 23rd 2017.

What are analysts saying about Intercept Pharmaceuticals stock?

Here are some recent quotes from research analysts about Intercept Pharmaceuticals stock:

  • Needham & Company LLC analysts commented, "Intercept reported 4Q16 financial results today. Ocaliva sales were $13.4M, compared to our $9.0M and consensus $7.8M est. Mgmt cited better than expected gross:net. No sales guidance was issued, as expected, although mgmt indicated 1Q17 sales will only be modestly above 4Q16, w/ expectations for gross:net to worsen. As a reminder, drug was launched in Jun 2016 for treatment of PBC. Ocaliva launch is progressing well, but we believe this is already factored in stock. Mgmt recently negotiated changes to Phase 3 REGENERATE NASH trial design, allowing for smaller pt population. We expect a favorable outcome, but note results will still not be available until 1H19." (2/23/2017)

  • Cantor Fitzgerald analysts commented, "With concerns in Nov. 2016 to achieve REGENERATE interim enrollment by 1H17, Intercept amended protocols and now expects completion by mid-2017." (2/13/2017)

  • Wedbush analysts commented, "Intercept announced two protocol amendments to the Phase 3 REGENERATE trial including updating the definition of NASH resolution to the newer objective definition and only requiring statistical significance of one of the two components (NASH resolution without worsening of fibrosis and improvement in fibrosis without worsening of NASH) making up the co-primary endpoint in the ITT patient population. The previous definition of NASH resolution was the absence (score of zero) of at least one of the three components of NASH (steatosis, ballooning, or inflammation; Gastroenterology 2016; 150:1147-59) to the absence of ballooning (score to zero from 0-2) and residual (score of 1) or no (score of 0) inflammation (from 0-3). The new objective definition of NASH resolution is in-line with Genfit's ongoing Phase 3 NASH trial (March 10, 2016 press release)." (2/8/2017)
  • According to Zacks Investment Research, "Intercept received a major boost with the approval of its lead drug, Ocaliva, in combination with ursodeoxycholic acid (UDCA), for the treatment of primary biliary cholangitis (PBC) in both the U.S. and the EU. Successful commercialization of the drug will significantly boost the company’s revenues, going forward. The PBC market holds strong potential.  We are also encouraged by Intercept’s efforts to develop the drug in additional indications. Loss estimates have narrowed lately ahead of the company’s Q4 earnings release. The company has a positive record of earnings surprises in the recent quarters. Moreover, the company’s share price outperformed the industry in the last twelve months. However, expenses will continue to rise in the coming quarters as the company prepares for a potential launch of Ocaliva. We also remain concerned about the lack of other late-stage candidates in Intercept’s pipeline." (1/19/2017)

  • FBR & Co analysts commented, "At the annual meeting of the AASLD (American Association for the Study of Liver Diseases) held in Boston, Massachusetts, November 11–15, Intercept Pharmaceuticals and its collaborators presented results from three post-hoc analyses of the completed POISE Phase III trial with Ocaliva in patients with primary biliary cholangitis (PBC). In parsing through the analyses presented, we came away with a more definitive picture of the wealth of data generated by POISE, which is the pivotal trial that gained Ocaliva FDA approval in May 2016. Importantly, the analyses provide data that may be added to the compendium of information that supports Ocaliva’s nascent potential in PBC." (11/18/2016)

Who owns Intercept Pharmaceuticals stock?

Intercept Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional investors include FMR LLC (15.00%), Orbimed Advisors LLC (4.51%), State Street Corp (3.03%), Marshall Wace LLP (0.41%), White Square Capital LLP (0.26%) and National Planning Corp (0.21%). Company insiders that own Intercept Pharmaceuticals stock include Barbara Gayle Duncan, David Shapiro, Jonathan Silverstein, Klaus R Dr Veitinger, Lisa Bright, Luciano Adorini, Mark Pruzanski, Nicole Williams, Orbimed Advisors Llc and Rachel Mcminn.

Who sold Intercept Pharmaceuticals stock? Who is selling Intercept Pharmaceuticals stock?

Intercept Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Credit Agricole S A, Metropolitan Life Insurance Co. NY, Van ECK Associates Corp, First Republic Investment Management Inc., Federated Investors Inc. PA and Guggenheim Capital LLC. Company insiders that have sold Intercept Pharmaceuticals stock in the last year include Barbara Gayle Duncan, David Shapiro, Lisa Bright, Mark Pruzanski and Rachel Mcminn.

Who bought Intercept Pharmaceuticals stock? Who is buying Intercept Pharmaceuticals stock?

Intercept Pharmaceuticals' stock was purchased by a variety of institutional investors in the last quarter, including State Street Corp, Marshall Wace LLP, White Square Capital LLP, ING Groep NV, FMR LLC, A.R.T. Advisors LLC, Numeric Investors LLC and State Board of Administration of Florida Retirement System.

How do I buy Intercept Pharmaceuticals stock?

Shares of Intercept Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Intercept Pharmaceuticals stock cost?

One share of Intercept Pharmaceuticals stock can currently be purchased for approximately $115.93.

Intercept Pharmaceuticals (NASDAQ:ICPT) Chart for Friday, February, 24, 2017

Institutional Ownership Chart

Institutional Ownership by Quarter for Intercept Pharmaceuticals (NASDAQ:ICPT)

Earnings History Chart

Earnings by Quarter for Intercept Pharmaceuticals (NASDAQ:ICPT)

Dividend History Chart

Dividend Payments by Quarter for Intercept Pharmaceuticals (NASDAQ:ICPT)

Last Updated on 2/24/2017 by Staff